Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T18:42:52.966Z.
Calculation as of: 2026-10-06T18:42:52.966Z.
Quote observation: 2026-10-06T18:38:28.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ee26685a5d6dda55be8f646f5bdd6a865e7c0271b97e419ee039990db4d6ed05
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.11M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.02M
EBITDA Yield
N/A
TTM Avg
86.52%
3Y Avg
86.52%
5Y Avg
86.52%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | $1.14M | N/A | N/A | N/A | N/A |
| IM Cannabis Corp. (IMCC)vs › | $1.13M | N/A | 8.30% | 8.30% | 8.30% |
| Cellyan Biotechnology Co., Ltd (HKPD)vs › | $1.11M | N/A | N/A | N/A | N/A |
| Clearmind Medicine Inc. (CMND)vs › | $1.07M | N/A | N/A | N/A | N/A |
| Aspire Biopharma Holdings, Inc. (ASBP)vs › | $1.02M | N/A | 86.52% | 86.52% | 86.52% |
| NewcelX Ltd. (NCEL)vs › | $1.37M | N/A | N/A | N/A | N/A |
| Genprex, Inc. (GNPX)vs › | $1.34M | N/A | N/A | N/A | N/A |
| Artelo Biosciences, Inc. (ARTL)vs › | $1.34M | N/A | N/A | N/A | N/A |
| GlucoTrack, Inc. (GCTK)vs › | $905892.00 | N/A | 0.07% | 0.06% | 0.06% |
| Jupiter Neurosciences, Inc. (JUNS)vs › | $1.41M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
